Regencell Bioscience (NASDAQ:RGC) Stock Price Down 5.1% – Should You Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) traded down 5.1% during trading on Wednesday . The company traded as low as $16.18 and last traded at $15.8750. 17,632 shares changed hands during trading, a decline of 94% from the average session volume of 276,591 shares. The stock had previously closed at $16.73.

Key Regencell Bioscience News

Here are the key news stories impacting Regencell Bioscience this week:

• Negative Sentiment: A class action lawsuit has been filed against Regencell and certain officers, with plaintiffs alleging false and misleading statements, market-manipulation vulnerability, and exposure to regulatory and DOJ scrutiny. Article Title
• Negative Sentiment: Several law firms are actively urging investors to join or lead the case, highlighting potential compensation claims and a June 23 lead-plaintiff deadline, which keeps negative legal attention on the stock. Article Title
• Neutral Sentiment: Additional notices from firms including Rosen, Faruqi & Faruqi, Holzer & Holzer, Portnoy, and The Gross Law Firm mainly reiterate the lawsuit timeline and investor deadline rather than adding new company-specific developments.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Regencell Bioscience Price Performance

The stock’s 50-day moving average price is $26.21 and its 200-day moving average price is $25.79.

Regencell Bioscience (NASDAQ:RGC) last posted its quarterly earnings results on Friday, May 8th. The company reported $0.00 earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Squarepoint Ops LLC bought a new position in shares of Regencell Bioscience in the 2nd quarter worth about $1,701,000. BNP Paribas Financial Markets acquired a new stake in shares of Regencell Bioscience in the 2nd quarter worth about $768,000. XTX Topco Ltd acquired a new stake in shares of Regencell Bioscience in the 3rd quarter worth about $598,000. Vident Advisory LLC increased its holdings in shares of Regencell Bioscience by 65.7% in the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock worth $629,000 after acquiring an additional 11,866 shares during the period. Finally, Bank of America Corp DE increased its holdings in shares of Regencell Bioscience by 59,113.8% in the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after acquiring an additional 17,143 shares during the period. 0.13% of the stock is currently owned by institutional investors.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.